(Press-News.org) Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney disease.
The project is a bold step towards first-in-class therapy, harnessing a cutting-edge gene analysis approach augmented with AI and an emerging quantum computing platform.
This award aims to accelerate the drug development pathway and foster the creation of new therapeutic companies in Singapore.
Singapore, 13 August 2025—65LAB has awarded US$1.5 million (approx. S$1.9 million) to Professor Enrico Petretto to advance a breakthrough drug discovery platform developed at Duke-NUS Medical School. The project aims to deliver first-in-class antifibrotic therapies for lung and kidney diseases—conditions that currently have no effective treatment. The platform, known as Systems Genetics, integrates computational biology with Artificial Intelligence (AI) algorithms and is being enhanced with emerging quantum computing approaches.
65LAB is a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund, as well as global life science company Evotec, set up to drive scientific advancement and create new biotech ventures from Singapore. 65LAB Expert-in-Residence Stephen Courtney will provide venture-building guidance to Professor Petretto to develop a commercialisation strategy and advance the project towards company formation.
This award is further supported with a US$390,000 (approx. S$500,000) investment from Duke-NUS’ early-stage innovation fund and incubation programme, LIVE Ventures, which helps bridge the gap between academic discovery and commercial development.
Fibrosis, the formation of damaged and scarred extra tissues, can lead to organ failure. Conditions like idiopathic pulmonary fibrosis (a type of lung disease) affect an estimated 1 in 10,000 people in Asia-Pacific[1], while chronic kidney disease is a growing health burden, projected to affect one in four residents in Singapore by 2035. Professor Petretto's innovation directly addresses this huge unmet need by identifying molecules that can potentially be developed into new antifibrotic drugs.
Professor Enrico Petretto, Director of Duke-NUS’ Centre for Computational Biology, said:
“We are heartened by the results of our pre-clinical studies, which show at least a 50 per cent reduction in fibrosis in scarred tissues treated with our newly discovered molecules. These compounds work by blocking the activity of a key gene that drives tissue scarring in various diseases. 65LAB’s award and the additional funding from LIVE Ventures will enable my team to accelerate the development of these molecules as antifibrotic drugs for clinical testing and future therapeutic use.”
Prof Petretto’s work builds on his previous discovery of WWP2, a key gene driving tissue fibrosis in multiple conditions, including lung, heart and kidney disease. The discovery was made using his pioneering Systems Genetics approach. His team has since integrated Artificial Intelligence for large-scale high-throughput in silico screening, which allows them to sieve through more than 15 billion molecules. He is also advancing the integration of quantum computing to further enhance this powerful drug discovery platform.
Dr Chen Huimei, Principal Research Scientist at Duke-NUS’ Centre for Computational Biology and co-Principal Investigator on the project, said:
“Using our computational platform, our team can quickly identify optimal drug targets for complex diseases. We can also widen our candidate pool, improving our chances of discovering molecules that can effectively block the WWP2 gene.”
Next, Prof Petretto’s team aims to work with partners to test and develop their small-molecule inhibitors into antifibrotic drugs. Prof Petretto’s commercialisation aspirations are actively strengthened by Duke-NUS’ Centre for Technology and Development, which is protecting the novel drug targets and new molecular entities through strategic patent filings.
Forging Partnerships to Drive Biotech Venture Creation
The award by 65LAB underscores the importance of close partnerships between academic institutions and industry leaders in accelerating the commercialisation of promising innovations. 65LAB, coupled with early-stage venture funding from Duke-NUS’ incubator LIVE Ventures, creates a robust ecosystem to nurture scientific advancements into new therapeutic companies from Singapore, addressing critical health challenges globally.
Prof Petretto’s project was selected through a competitive evaluation process and received unanimous support from 65LAB’s investors and partners.
Dr. Pei-Sze Ng, Chair of 65LAB Joint Steering Committee and Investment Director at Leaps by Bayer said:
“This award enabling Professor Petretto to advance his groundbreaking work is central to 65LAB’s mission. By combining world-class academic research with targeted funding and industry expertise, we're not just accelerating drug discovery; we’re actively fostering the growth of Singapore’s biotech venture ecosystem and bringing innovative therapies closer to patients who desperately need them.”
Associate Professor Christopher Laing, Vice-Dean for Innovation and Entrepreneurship at Duke-NUS, said:
“The investment is testimony to the commercialisation potential of Enrico’s Systems Genetics pipeline. This project could bring a new therapy to market to treat patients with chronic diseases marked by fibrosis. It is also an affirmation of a robust platform for AI-driven target discovery, which promises more investible opportunities in the future.”
The first award by 65LAB was made in July 2024—Associate Professor Lena Ho, also from Duke-NUS, received funding of US$1.5 million for her project developing microproteins into therapeutic targets to treat chronic inflammation.
###
About Duke-NUS Medical School
Duke-NUS is Singapore’s flagship graduate-entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted ‘Clinicians Plus’ poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five Signature Research Programmes and ten Centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore’s largest healthcare group. This strategic alliance has led to the creation of 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives.
For more information, please visit www.duke-nus.edu.sg
About 65LAB
65LAB was founded to turn innovations into lifesaving medicines. Our mission is to drive scientific advancement and create new therapeutic companies from Singapore. We accelerate the drug discovery pathway and new company formation by bringing together the expertise of global partners — leading research institutions in Singapore, established life science investors, and reputed drug discovery and development company Evotec. 65 pays homage to the year Singapore became an independent nation. It is also Singapore’s country code.
For more information, please visit 65lab.sg
[1] Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respiratory research. 2021 Dec;22:1-0.
END
New York, NY (August 14, 2025) – Researchers at the Icahn School of Medicine at Mount Sinai have found that prenatal exposure to acetaminophen may increase the risk of neurodevelopmental disorders, including autism spectrum disorder and attention-deficit/hyperactivity disorder (ADHD), in children. The study, published today in BMC Environmental Health, is the first to apply the rigorous Navigation Guide methodology to systematically evaluate the rigor and quality of the scientific literature.
Acetaminophen (often sold under the brand name Tylenol®, and known as paracetamol outside the United States and Canada) is the most commonly used over-the-counter ...
SCOTTSDALE, Ariz. — Aug. 14, 2025 — Nicholas J. Schork, Ph.D., an international authority on human longevity and health maintenance, has joined HonorHealth Research Institute as Research Director of Longevity, Prevention and Interception.
Dr. Schork heads a unique laboratory that is part of the Research Institute’s newly created Center for Translational Science, and his appointment is part of a significant push on the part of the Institute to expand its collaborations and the realm of precision medicine possibilities; providing specific answers to individual patients with ...
In the latest evidence that meaningful social connections bolster health, a team from The University of Texas at Austin and University of Massachusetts Boston has found that regular time spent helping outside the home significantly slows cognitive decline in middle-age and older adults.
The new study of more than 30,000 adults in the U.S. looking at individuals over two decades found that the rate of cognitive decline associated with aging fell by 15%-20% for people who formally volunteer their services or who help in more informal ways with neighbors, family or friends outside the home on a regular basis. This cognitive benefit was consistently observed when individuals ...
A CU Boulder-led initiative to reduce youth violence in hard-hit Denver neighborhoods was associated with a 75% decline in arrests for murder, assault, robbery and other youth crimes in recent years, new research shows.
“We now have concrete data to show that when communities come together and mobilize, we can prevent youth violence, even in urban settings with a very high burden,” said senior author Beverly Kingston, director of CU’s Center for the Study and Prevention of Violence (CSPV).
The study, published ...
Drug treatment for people with newly diagnosed attention deficit hyperactivity disorder (ADHD) is associated with significantly reduced risks of suicidal behaviours, substance misuse, transport accidents, and criminality, finds a study published by The BMJ today.
The researchers say this is the first study of its kind to show beneficial effects of ADHD drug treatment on broader clinical outcomes for all ADHD patients and should help inform clinical practice.
ADHD affects around 5% of children and 2.5% of adults worldwide and is associated with adverse outcomes including suicidal behaviours, substance ...
AI Chatbots that provide human-like interactions are used by millions of people every day, however new research has revealed that they can be easily manipulated to encourage users to reveal even more personal information.
Intentionally malicious AI chatbots can influence users to reveal up to 12.5 times more of their personal information, a new study by King’s College London has found.
For the first time, the research shows how conversational AI (CAIs) programmed to deliberately extract data can successfully encourage users to reveal private information using known prompt techniques and psychological ...
(MEMPHIS, Tenn. – August 13, 2025) Spinal muscular atrophy (SMA) is a rare genetic condition that causes progressive muscle weakness, which, when untreated, prevents infants with the most severe form from gaining motor development — never gaining the ability to sit — and typically leads to death before 2 years of age. The oral drug risdiplam benefits symptomatic patients with improved motor function and increased survival, but had only been Food and Drug Administration–approved for use in patients aged 2 months and older. An international consortium, co-led by Richard Finkel, MD, of St. ...
As the nation gears up for the rollout of an updated COVID-19 vaccine, a new study shows the economic benefits of continued broad vaccination in adults.
In fact, the country would ultimately save more money that it would spend on vaccinating every person over age 65 with a single dose of an updated mRNA vaccine against coronavirus, the study concludes.
That’s because of the power of the vaccine to prevent deaths, hospitalizations, short- and long-term illness and lost productivity such as lost workdays in this age group, the researchers report based on a computer model. The model focused on people without immunocompromising conditions or medications.
Meanwhile, ...
Study after study shows that walking is very good for those who are able, and generally more is better. A 2023 study found that even 4,000 steps a day improves all-cause mortality risk. (The U.S average is 4,000 to 5,000.) For each 1,000 extra daily steps, risk decreased by 15%.
Walk Scores have been used since 2007 to quantify how quickly people can typically walk to amenities like grocery stores and schools in an area. Cities are assigned scores from 0 to 100; for instance, Seattle’s 74 means it’s “very walkable.” It may seem self-evident that in cities ...
Cancer is the leading cause of disease-related death in childhood. This is in part due to cancer-associated genes called oncogenes that can be found far from chromosomes in cell nuclei on ring-shaped DNA inside tumor cells.
Circular extra-chromosomal DNA elements (ecDNA) are pieces of DNA that have broken off normal chromosomes and then been wrongly stitched together by DNA repair mechanisms. This phenomenon leads to circular DNA elements floating around in a cancer cell.
“We have shown that these ecDNAs are ...
